ADAGIO THERAPEUTICS, INC.

(ADGI)
  Report
Real-time Estimate Cboe BZX  -  12:22 2022-08-16 pm EDT
3.795 USD   -4.89%
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlights - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADAGIO THERAPEUTICS, INC. : Other Events (form 8-K)

05/19/2022 | 05:17pm EDT

Item 8.01 Other Events.

On May 19, 2022, Adagio Therapeutics, Inc. (the "Company") announced that it will postpone the Company's 2022 Annual Meeting of Stockholders (the "Annual Meeting"), previously scheduled for May 26, 2022, and with respect to which the Company had filed a preliminary proxy statement with the Securities and Exchange Commission (the "SEC") on April 26, 2022. The Company will also set a new record date, which will be announced along with the new Annual Meeting date at a later time.

The Company has received notice from Mithril II LP, a Delaware limited partnership ("Mithril"), which beneficially owns approximately 10.2% of the Company's common stock, expressing the intention of Mithril to nominate three nominees for election to the Company's Board of Directors (the "Board") at the Annual Meeting. Mithril and the other participants in its proxy solicitation (collectively, the "Mithril Group") have filed a definitive proxy statement with the SEC in which they indicate beneficial ownership of approximately 49.3% of the shares of the Company's common stock outstanding on March 29, 2022. The three candidates (collectively, the "Mithril Nominees") nominated by Mithril are the only nominees that have been submitted for election at the Annual Meeting.

The Company will not be submitting a separate slate of nominees for election to the Board at the Annual Meeting. Consequently, the Company does not plan to solicit proxies from stockholders in connection with the Annual Meeting or plan to deliver a proxy statement or proxy solicitation materials to stockholders in connection with the Annual Meeting.

Pursuant to Rule 14c-2(a) of Regulation 14C of the Securities and Exchange Act of 1934, as amended, the Company has filed a preliminary information statement on Schedule 14C that contains additional information about the Annual Meeting. To comply with the (i) mandatory preliminary review period under Rule 14c-5 of Regulation 14C, and (ii) requirement that the Annual Meeting be held at least 20 days after the Company's mailing of a definitive information statement, the date of the Annual Meeting must be postponed from its originally scheduled date.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ADAGIO THERAPEUTICS, INC.
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Adagio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15ADAGIO THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
08/15Adagio Therapeutics Q2 Net Loss Narrows
MT
08/15Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highligh..
GL
07/05ADAGIO THERAPEUTICS : Announces Results of Annual Meeting of Stockholders and Evolution of..
PU
07/05ADAGIO THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
07/05SECTOR UPDATE : Health Care Stocks Struggle Tuesday
MT
07/05SECTOR UPDATE : Health Care Stocks Retreating in Tuesday Trade
MT
07/05SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on ADAGIO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -271 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 434 M 434 M -
EV / Sales 2022 -
EV / Sales 2023 16,9x
Nbr of Employees 102
Free-Float 67,2%
Chart ADAGIO THERAPEUTICS, INC.
Duration : Period :
Adagio Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAGIO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 3,99 $
Average target price 3,83 $
Spread / Average Target -3,93%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial & Business Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAGIO THERAPEUTICS, INC.-45.04%434
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-20.33%40 492
BIONTECH SE-36.97%39 486